Nilotinib
- PDF / 170,049 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 7 Downloads / 153 Views
1 S
Pancreatitis: case report A 78-year-old man developed pancreatitis during treatment with nilotinib for myelodysplastic syndrome (MDS) and chronic myelogenous leukaemia (CML). The man, who presented with progressively worsening macrocytic anaemia, was diagnosed with MDS in 2007. In September 2009, he was also diagnosed with CML. He started receiving imatinib for MDS and CML. Within 3 months, he became PCR negative, and his haemoglobin returned to baseline. In May 2010, he experienced discomfort in his left arm and was detected with a large lytic lesion within the left humerus. He then underwent operative fixation with intramedullary nail placement. He was also detected with acute myeloid leukaemia, which was a blastic transformation from the CML clone. He was then treated with postoperative radiation. Later, imatinib was switched to nilotinib 400mg twice daily [route not stated]. It maintained a major molecular response. However, he experienced a 10-fold increase in his pancreatic enzymes and subsequently developed pancreatitis, which was suspected to be induced by nilotinib [time to reaction onset not stated]. The man’s therapy with nilotinib was therefore changed to dasatinib. Despite dose reduction of dasatinib, he developed bilateral pleural effusions [aetiology of pleural effusion not stated] and required multiple thoracenteses. In July 2012, the man’s therapy was changed back to nilotinib at a lower dose of 300mg twice daily, without recurrence of pancreatitis. Thereafter, he remained in major molecular remission and without local or systemic leukaemic recurrence. He required darbopoetin for his anaemia. He remained in remission with respect to his blastic transformation. In 2014, he died of pneumonia [aetiology of pneumonia not stated]. Reap L, et al. Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia. Leukemia Research Reports 14: 2020. Available from: URL: 803518188 http://doi.org/10.1016/j.lrr.2020.100225
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
